Vancouver, BC – February, 2019 - Medipure Holdings Inc., a biopharmaceutical incubator committed to discovering and developing proprietary endocannabinoid system-based prescription drugs for targeted diseases by regulating specific molecular mechanisms, today announced the appointment of Dr. Miroslav Weiss as Medical Director of its subsidiary in Croatia.
Dr. Weiss has a long history of clinical and health management experience in Zagreb, including a dual role as pediatrician and Director of Quality Control and Management at the Hospital for Children with Chronic Diseases. He currently practices in the Department of Pediatrics at University Clinical Hospital Centre.
“Dr. Weiss will be a welcome and valued addition to our senior leadership team in Croatia,” said Boris Weiss, CEO of Medipure. "His clinical background and health management experience in key health delivery hubs in Croatia will be instrumental to our success.“
In August, Medipure announced the creation of a subsidiary, Medipure d.o.o., in Croatia through which R&D will focus on clinical trials and pharmacology. Along with full analytical labs, this site will house a GMP facility allowing the Company to produce drugs in compliance with the European regulatory standards necessary to support clinical trials on the road to regulatory approvals and commercialization.
Dr. Weiss spent his school years in Zagreb, Croatia and then moved to Canada where he graduated from the Business Administration Program at Capilano College and achieved a Bachelor of Arts degree from the University of BC. He later graduated from the School of Medicine in Zagreb, Croatia.
For more information, please visit: http://medipurepharmaceuticals.com
Medipure is a biopharmaceutical incubator committed to discovering and developing proprietary endocannabinoid system-based prescription drugs for targeted diseases by regulating specific molecular mechanisms. Our core products target specific disease areas including pain management, mood disorders/anxiety, nausea, appetite, oncology, arthritis, dermatology and fatty liver disease (NASH). Medipure's research and development is focused on having the greatest impact and benefit for patients worldwide. At the same time, we aim to make sure that our products are approved by regulators and well understood by physicians, healthcare providers and prospective patients.